Some other studies showed that serum levels of TGF-β1 were lower in Egyptian SLE patients (unknown treatment) than those in controls, and LN patients (unknown treatment) revealed lower serum levels of TGF-β1 than in non-LN patients (100–102). Here, TGFB1 is linked to lobular neoplasia.